研究目的
To develop a novel strategy for glioma tracing and to carry out accurate surgical treatment under its guidance, utilizing c(RGDyk)-modified nanoparticles encapsulating quantum dots as a stable fluorescence probe for imaging-guided surgical resection of glioma under the auxiliary UTMD.
研究成果
QDs-c(RGDyk)NP may be very promising as a traceable drug for accurate surgical resection of glioma, offering a new, safe, and effective strategy for improving the quality of glioma surgical resection.
研究不足
The study acknowledges the toxicity of quantum dots and the challenges in maximizing the binding of QDs to glioma while reducing toxicity to other normal organs. The size of the QD formulations and their accumulation in the RES are also noted as limitations.
1:Experimental Design and Method Selection:
Synthesis of c(RGDyk)-poloxamer 188 and preparation of QDs-c(RGDyk)NP via film hydration followed by sequential extrusion.
2:Sample Selection and Data Sources:
C6 glioma cells and adult male Sprague-Dawley (SD) rats for in vitro and in vivo studies.
3:List of Experimental Equipment and Materials:
ZnCdSe/ZnS QDs, Poloxamer 188, MES, EDC, NHS, c(RGDyk), C6 cells, CCK-8 kit, DMEM, SF6 MBs, anti-GFAP antibody.
4:Experimental Procedures and Operational Workflow:
Characterization of QDs-c(RGDyk)NP, in vitro cytotoxicity assay, in vitro cellular uptake experiments, in vivo imaging of glioma using QDs-c(RGDyk)NP combined with UTMD, accurate surgical resection of glioma via fluorescence imaging, and in vivo toxicity evaluation.
5:Data Analysis Methods:
Statistical analyses using GraphPad Prism version 7 for Windows.
独家科研数据包,助您复现前沿成果,加速创新突破
获取完整内容